Gilead to Buy Arcellx for $7.8 B to Secure Multiple Myeloma Cell Therapy
Gilead Sciences will acquire Arcellx for $7.8 billion in cash to secure full rights to Anito-cel, Arcellx’s promising cell therapy for relapsed multiple myeloma. The agreement bolsters Gilead’s oncology pipeline and positions it to compete more aggressively in the cell therapy market.
1. Deal Structure
Gilead agreed to pay $7.8 billion in cash to acquire all outstanding shares of Arcellx, granting it complete global rights to Anito-cel. The transaction is expected to finalize in 2026 after customary regulatory reviews.
2. Therapy Candidate
Anito-cel is Arcellx’s lead cell therapy for relapsed or refractory multiple myeloma, with early clinical data indicating robust responses in treated patients. Its differentiated profile in the CAR-T segment underpins Gilead’s willingness to invest at a high valuation.
3. Strategic Impact
The acquisition accelerates Gilead’s expansion into cell therapy, supplementing its existing oncology portfolio and intensifying competition with rival developers. Full control of Anito-cel enables Gilead to integrate development, manufacturing and commercialization to maximize market potential.